Clinical Trials Directory

Trials / Conditions / Hepatitis A

Hepatitis A

71 registered clinical trials studyying Hepatitis A7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingComparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Vir
NCT07525401
Combined Military Hospital, PakistanN/A
Not Yet Recruitingthe Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
NCT07338851
China National Biotec Group Company Limited
RecruitingRisk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
NCT07358910
Institut Pasteur du Cambodge
Not Yet RecruitingImmunity With Acute Hepatits A
NCT06942962
Assiut University
Not Yet RecruitingLong-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
NCT07032610
Chiang Mai University
RecruitingImmunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After
NCT06978621
Chiang Mai UniversityPhase 3
Not Yet RecruitingPhase IV Study of Concomitant Administration of the sIPV and HepA
NCT06460545
Institute of Medical Biology, Chinese Academy of Medical SciencesPhase 4
CompletedImmunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adole
NCT06298708
Chiang Mai UniversityPhase 3
UnknownPersistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.
NCT06184230
Best Healthcare Inc.Phase 4
CompletedImmunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
NCT06576024
LiuZhou People's HospitalPhase 4
Active Not RecruitingImmunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
NCT06058416
Sinovac Biotech Co., LtdPhase 4
UnknownTo Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24m
NCT05613127
Boryung Biopharma Co., Ltd.Phase 3
CompletedWhat is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years
NCT04638335
University of Lausanne Hospitals
WithdrawnIncreasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
NCT03445416
Ann & Robert H Lurie Children's Hospital of ChicagoN/A
WithdrawnImmunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccina
NCT03183492
GlaxoSmithKlinePhase 4
CompletedEffects of Aging on Primary and Secondary Vaccine Responses
NCT03312699
Stanford UniversityPhase 1
CompletedEffectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
NCT03855176
National Taiwan University HospitalPhase 4
UnknownComparative Immunogenicity Study of Two Hepatitis A Vaccines
NCT03231605
China National Biotec Group Company LimitedPhase 4
UnknownSafety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine
NCT03330171
University of Witwatersrand, South AfricaPhase 4
WithdrawnHepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
NCT02605538
Karolinska University HospitalN/A
WithdrawnEvaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20
NCT02135666
GlaxoSmithKlinePhase 4
WithdrawnEvaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25
NCT02124785
GlaxoSmithKlinePhase 4
CompletedStudy to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico
NCT02112890
GlaxoSmithKline
CompletedComparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis
NCT02445703
Sinovac Biotech Co., LtdPhase 4
CompletedSafety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adole
NCT02011763
Sanofi Pasteur, a Sanofi CompanyPhase 4
CompletedThe Effects of Honey, as a Dietary Supplement in Children With Hepatitis A
NCT02300792
Ain Shams UniversityPhase 2
CompletedThe Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
NCT01949857
Institute of Medical Biology, Chinese Academy of Medical SciencesPhase 4
CompletedRegulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)
NCT01838070
Sanofi Pasteur, a Sanofi Company
CompletedImmunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
NCT02601040
Jiangsu Province Centers for Disease Control and PreventionPhase 4
CompletedStudy to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate V
NCT01453348
Novartis VaccinesPhase 3
CompletedImmunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients
NCT01341808
Asan Medical CenterPhase 4
CompletedHepatitis A Vaccination in the Elderly
NCT01353989
Rijnstate Hospital
CompletedImmunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines
NCT01252680
Sinovac Biotech Co., LtdPhase 4
CompletedA Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Chi
NCT01349829
Crucell Holland BVPhase 4
CompletedSeroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussi
NCT01160081
GlaxoSmithKline
CompletedLong-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult
NCT01037114
GlaxoSmithKlinePhase 4
CompletedAntibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
NCT01000324
GlaxoSmithKlinePhase 4
UnknownSerological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery
NCT00926419
University of Sao Paulo General HospitalPhase 2 / Phase 3
CompletedEvaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™
NCT00875485
GlaxoSmithKlinePhase 4
CompletedThe Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children
NCT02002065
Sinovac Biotech Co., Ltd
CompletedComparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adult
NCT01865968
Sinovac Biotech Co., LtdPhase 4
CompletedStudy of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
NCT00735644
Sanofi Pasteur, a Sanofi CompanyPhase 3
CompletedEvaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Va
NCT00684671
GlaxoSmithKlinePhase 4
CompletedImmunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
NCT00621764
Sanofi Pasteur, a Sanofi CompanyPhase 2
CompletedStudy to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults
NCT00603252
GlaxoSmithKlinePhase 4
CompletedImmunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose
NCT00483470
Sanofi Pasteur, a Sanofi CompanyPhase 3
CompletedHepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V2
NCT00326183
Merck Sharp & Dohme LLCPhase 4
CompletedLong Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered W
NCT01307436
Crucell Holland BVPhase 3
UnknownHepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2
NCT00451984
Aalborg University HospitalPhase 3
CompletedImmunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Va
NCT00313950
Sanofi Pasteur, a Sanofi CompanyPhase 4
CompletedSafety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00338351
GlaxoSmithKlinePhase 2
CompletedSafety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine
NCT00534885
Sinovac Biotech Co., LtdPhase 4
CompletedSafety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population
NCT00237991
GlaxoSmithKline
CompletedLong-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,
NCT00289770
GlaxoSmithKlinePhase 3
CompletedLong-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,
NCT00289718
GlaxoSmithKlinePhase 3
CompletedA Randomized Trial of Vaccine Adherence in Young Injection Drug Users
NCT00244374
University of California, San FranciscoN/A
CompletedSafety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine
NCT01405677
Crucell Holland BVPhase 2
CompletedLong-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared
NCT00197119
GlaxoSmithKlinePhase 3
CompletedLong-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6
NCT00289744
GlaxoSmithKlinePhase 3
CompletedLong-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected Accordi
NCT00289757
GlaxoSmithKlinePhase 4
CompletedLong-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected Accordin
NCT00291876
GlaxoSmithKlinePhase 4
CompletedEffect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A &
NCT00289731
GlaxoSmithKlinePhase 4
CompletedImmunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilu
NCT00197236
GlaxoSmithKlinePhase 3
CompletedLong Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Va
NCT00197184
GlaxoSmithKlinePhase 3
CompletedImmunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in
NCT00197015
GlaxoSmithKlinePhase 3
CompletedImmune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Childr
NCT00197002
GlaxoSmithKlinePhase 3
CompletedA Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepati
NCT00139139
Centers for Disease Control and PreventionN/A
CompletedLong Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis
NCT00197171
GlaxoSmithKlinePhase 3
CompletedComparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi
NCT00197249
GlaxoSmithKlinePhase 3
TerminatedA Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
NCT00119743
GlaxoSmithKlinePhase 3
CompletedImmunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
NCT00139113
Centers for Disease Control and PreventionPhase 4